Biogen’s Contemporary Alzheimer’s Drug Meets Slack Rollout

Biogen Inc. reported slack uptake of its new Alzheimer’s illness drug Aduhelm within the third-quarter, as some doctors stayed on the fence about whether to prescribe the drug and others struggled to coordinate the advanced assignment of onboarding new sufferers for drugs.

Aduhelm sales had been $300,000 within the first fat quarter since the drug used to be accredited in June, falling immediate of the $12 million projected by analysts, in accordance with FactSet. The Cambridge, Mass., firm continues to inquire of minimal Aduhelm earnings this year, however sales must peaceful commence ramping up in 2022, Biogen acknowledged on Wednesday.

Be taught More


Read Previous

‘Down the rabbit hole’: Arizona GOP goes rotund fringe

Read Next

A 365 days after the #EndSARS protests, what has changed?

Leave a Reply

Your email address will not be published. Required fields are marked *